Although imatinib is currently used as the first-line therapy for CML patients, a significant number of patients develop resistance, usually due to point mutations in the tyrosine kinase domain of BCR-ABL protein. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.